Oral Research Compounds: A Review of BPC-157, TB-500, Cabergoline, GW-501516, and Clenbuterol

EXOMA Scientific Team · Publicado el 21 de mayo de 2026 · Actualizado el 29 de agosto de 2026

Exploration of orally administered compounds such as BPC-157, TB-500, Cabergoline, GW-501516 (Cardarine) and Clenbuterol, analyzing their mechanisms of action and the available preclinical scientific evidence. This article focuses on their potential in various biological processes investigated in laboratory settings.

Introduction

Preclinical research in the field of bioactive compounds has shown a growing interest in various molecules administered by the oral route. These compounds present distinctive mechanisms of action that make them relevant for exploration in models in vitro e in vivo. This document offers a review of some of these compounds, including their properties, biological rationale and the preclinical scientific evidence that supports their investigation.

Compounds of the group

BPC-157 Arginate Oral and BPC-157 + TB-500 Oral Blend

The pentadecapeptide BPC-157 is a synthetic peptide derived from a natural protein found in gastric juice. It is known for its stability and bioavailability when administered orally, especially in its Arginate form, designed to improve its absorption. For more information, consult BPC-157 Arginate Oral.

It is sometimes formulated in combination with TB-500, a synthetic fragment of Tβ4, a multifunctional protein. This combination, available as BPC-157 + TB-500 Oral Blend, seeks to capitalize on possible synergistic effects in cellular and tissue processes.

Cabergoline

Cabergoline is a long-acting dopaminergic agonist derived from ergot. It acts selectively on dopamine D2 receptors. Its pharmacological profile makes it a subject of study for the modulation of dopaminergic pathways. More details can be found under Cabergoline.

Cardarine (GW-501516)

GW-501516, commonly known as Cardarine, is a peroxisome proliferator-activated receptor δ (PPARδ) agonist. This compound has been extensively studied for its involvement in the regulation of metabolism. Review the information at Cardarine (GW-501516).

Clenbuterol

Clenbuterol is a selective β2-adrenergic agonist. Although initially investigated for its bronchodilatory properties, in the context of preclinical research its impact on various tissues has been explored. For more information, consult Clenbuterol.

Compared mechanisms

The reviewed compounds exert their effects through different mechanisms:

• BPC-157 and TB-500: It has been postulated that BPC-157 exerts its effects through the modulation of growth factors and the stabilization of the intestinal epithelium. TB-500, for its part, contributes to cell migration and angiogenesis, processes crucial in tissue repair.
• Cabergoline: It acts as an agonist of the D2 dopaminergic receptors, which results in the inhibition of prolactin release, among other dopaminergic effects.
• Cardarine (GW-501516): By activating PPARδ, GW-501516 influences the expression of genes involved in lipid and carbohydrate metabolism, promoting fatty-acid oxidation and the improvement of insulin sensitivity in preclinical models.
• Clenbuterol: Its action is based on binding to β2-adrenergic receptors, which leads to relaxation of smooth muscle and stimulation of lipolysis.

Preclinical evidence

The scientific literature has documented a variety of findings in studies in vitro e in vivo with these compounds:

• BPC-157: Animal research has suggested its potential in the repair of gastrointestinal tissues, wound healing, and recovery from musculoskeletal injuries (Seiwerth et al., 2018). Its action has been associated with the modulation of collagen synthesis and angiogenesis.
• TB-500: Studies in animal models have indicated that TB-500 can promote the migration of endothelial cells and keratinocytes, which could accelerate angiogenesis and wound healing (Malinda et al., 2007).
• Cabergoline: In animal models, Cabergoline has been investigated for its effects on the reduction of prolactin secretion and its impact on certain neuroendocrine processes (Webster et al., 1992).
• Cardarine (GW-501516): Studies in rodents have demonstrated that GW-501516 can increase resistance to exercise due to the improvement of fatty-acid metabolism and mitochondrial biogenesis in skeletal muscle, as well as a weight reduction (Wang et al., 2004).
• Clenbuterol: Preclinical research has explored the effects of Clenbuterol on lipolysis and the preservation of muscle mass in animal models under certain conditions (Zeman et al., 1988).

Laboratory handling

The compounds mentioned are for exclusive research use. Storage under controlled conditions is recommended, away from light and humidity, and at specific temperatures to preserve their stability and purity. EXOMA ensures purity through HPLC analyses performed by the analytical laboratory Chromasys.

References

1. Sikirić P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. doi:10.2174/138161211796196954. PMID 21548867. (BPC-157; preclínico)
2. Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60(Supl 7):191-196. PMID 20388964. (BPC-157; animal e in vitro)
3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID 22074294. (Timosina β4/TB-500; revisión)
4. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. doi:10.1111/j.1749-6632.2010.05492.x. PMID 20536467. (review)

Products available at EXOMA

• BPC-157
• BPC-157 + TB-500
• Clenbuterol
• TB-500